Sign inJoin waitlistJoin the waitlist

AW

Adrian Wiestner

Tenured Senior Investigator, NHLBI · Clinical Center at the National Institutes of Health

Credentials: · · ·

History

Clinical Center at the National Institutes of Health
Present

Internal Medicine

Research

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma
Proceedings of the National Academy of Sciences of the United States of America · 2003 · 811 citations
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia
Blood · 2011 · Last of 24 authors · 709 citations
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
Cancer Cell · 2003 · 679 citations

CS
Clare Sun
49 papers · 11 as a fellow
Inhye Ahn
32 papers · 4 as a fellow
Wyndham Wilson
32 papers
GM
Gerald Marti
26 papers
MS
Maryalice Stetler-Stevenson
23 papers
Constance Yuan
18 papers
Nakhle Saba
17 papers
Stefania Pittaluga
17 papers
Irina Maric
15 papers
GA
Georg Aue
13 papers
CP
Christopher Pleyer
9 papers · 4 as a fellow
Jan Burger
7 papers

Grants

Tumor Microenvironment in CLL and MCL: Pathogenesis, Targets, and Therapy
National Heart, Lung, and Blood Institute · ZIA
Contact PI · $29.8M · National Heart, Lung, and Blood Institute
Immunotherapy of Low Grade Lymphoid Malignancies
National Heart, Lung, and Blood Institute · ZIA
Contact PI · $15.9M · National Heart, Lung, and Blood Institute
Novel Therapies for Mantle Cell Lymphoma: Targets, Mechanisms, and Prognosis
National Heart, Lung, and Blood Institute · ZIA
Contact PI · $3.2M · National Heart, Lung, and Blood Institute
Gene Expression Profiling/Chronic Lymphocytic Leukemia
National Heart, Lung, and Blood Institute · Z01
Contact PI · $2.5M · National Heart, Lung, and Blood Institute

Clinical trials

Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome
Principal investigator · Active not recruiting · Phase 1
National Heart, Lung, and Blood Institute (NHLBI)
2025–2027
Vaccine Responses in Patients With B Cell Malignancies
Principal investigator · Recruiting · Phase 4
National Heart, Lung, and Blood Institute (NHLBI)
2022–2036
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Principal investigator · Completed · Phase 2
National Heart, Lung, and Blood Institute (NHLBI)
2017–2026
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Principal investigator · Recruiting
National Heart, Lung, and Blood Institute (NHLBI)
2008